one year of referrals and hence the numbers were small. ' The second study covered three years and included larger numbers of babies, but only referrals made postnatally were considered. In both studies no account was taken of confounding variables that could influence neonatal mortality.
Our study of referrals to the regional perinatal centre included hospitals from all over Northern Ireland. Cross regional referrals are not made in Northern Ireland and it proved relatively easy to trace most (98 3%) of the obstetric and neonatal records during the three years. We also considered babies who were referred prenatally, and the only criterion for refusal was unavailability of an intensive care cot for neonates at the centre. As this was not a randomised study, we adjusted for confounding variables in comparing outcome in the groups.
Of babies initially refused admission to the centre, most (78 6%) were subsequently accepted into other neonatal intensive care units within Northern Ireland. There was no significant difference in outcome for babies managed in these units compared with those managed in the centre. In many cases, however, there was a considerable delay before babies refused admission to the centre could be given intensive care, and their long term outcome remains uncertain. We have shown previously that the incidence of handicap is significantly higher in babies referred for intensive care after birth compared with those accepted prenatally."' A delay in starting intensive care may therefore be important. Those babies who did not receive intensive care and remained in special care baby units had a greater than threefold increase in their odds on dying. In addition, survivors from these hospitals could be expected to have a higher incidence of handicap than those sent for intensive care, although follow up studies are needed to confirm this.
There was some imbalance in the indications for prenatal referral, particularly in the number of cases of pre-eclampsia and rhesus isoimmunisation. This reflects clinical practice in that delivery of mothers with these conditions can often be delayed until an intensive care cot becomes available.
The number of babies who needed intensive care but were refused admission may be an underestimate as obstetricians and paediatricians at the hospitals that refer such babies may have known that intensive care cots were not available at the centre and therefore did not request transfer. Examination of mortality related to birth weight in individual hospitals might clarify this further.
Our study confirmed the benefits of neonatal intensive care and its particular value in improving the survival of babies of low birth weight. Short term survival seemed to 
Abstract
Objective-To assess the prevalence ofcolourings and preservatives in drug formulations in the United Kingdom.
Design-Postal survey. Participants-All pharmaceutical manufacturers in the United Kingdom were requested to supply data on drug formulations with particular regard to the content of colourings and preservatives.
Main outcome measure-Prevalence in proprietary drugs of colourings or preservatives, or both, that have been implicated in adverse reactions. Computa^tion of a list of formulations of bronchodilators, antihistamines, and antibiotics that are free of such additives.
Results-A total of 118 out of 120 pharmaceutical companies supplied the data requested. In all, 2204 drug formulations were analysed and found to contain 419 different additives, of which .52 were colourings and preservatives that have been implicated in adverse reactions; 930 formulations contained such an additive. Tartrazine was the fourth most commonly occurring colouring, being present in 124 drug formulations.
Conclusion-Many drugs contain additives that help to identify them and prolong their shelf life but are implicated in adverse reactions in some people. Some form of labelling of drug additives would enable these people to avoid drugs containing such additives.
Introduction
Many additives are used in drugs by the pharmaceutical industry for a variety of reasons, including improved identification and stability. Although adverse reactions to drugs have been reported and investigated for many years, adverse reactions to drug additives such as colourings and preservatives have been reported only over the past 30 years.' 4 Some of the colourings and preservatives that are added to drugs are also added to foods, and various adverse reactions have been attributed to them, although the validity of reports has been questioned.5 Colourings, however, have been reported to cause urticaria6-'0 and preservatives, such as sulphites, to cause asthma."-" There is little evidence that food or drug additives cause hyperactivity in children'4 despite popular perceptions and the results of several studies."-"l
The prevalence ofadverse reactions to food additives BMJ VOLUME 299 9 SEPTEMBER 1989 is uncertain, but a survey in the United Kingdom in 1987 suggested that at least 001-0-23% of the population is affected.'9 To help doctors to prescribe suitable drugs for patients proved or suspected to be intolerant to colourings or preservatives, or both, we conducted a survey of drug additives with the cooperation of most drug manufacturers in the United Kingdom.
Methods
We posted a standard letter to drug manufacturers that requested details of their drug formulations with special regard to the content of colourings and preservatives. The information was entered into a database, and the data were analysed with regard to the additives most commonly reported to cause adverse reactions. The Comparisons with drug formulations in Europe are limited to data from a recent survey in Switzerland, from which it seems that the number of drugs containing azo dyes in that country is similar to that in the United Kingdom; tartrazine is the fourth commonest azo dye in both countries.22 The data from the present survey are as accurate as possible, but drug formulations are subject to change from time to time, and specific information should be requested from the manufacturer. We did not study generic drug formulations, although they probably contain additives implicated in adverse reactions.
The mechanism of intolerance to colourings and preservatives is unknown. There is little evidence to support an immunological mechanism, but some recent studies support a pharmacological mechanism.z42s As placebo controlled challenges should also be performed. 2 In 1986 compulsory labelling of foods containing* additives was introduced in the United Kingdom, and as a consequence the range and number of foods available without such additives has increased. Whether the prevalence of reactions to food additives has declined since then would be difficult to determine. Compulsory labelling of drugs containing additives exists in some countries and is under consideration in the United Kingdom. It would clearly be useful for doctors to be able to refer to the Association of the British Pharmaceutical Industry's data sheet compendium for guidance when they are prescribing drugs for patients who have been proved or are suspected to be intolerant to colourings or preservatives, or both. Drug manufacturers are usually helpful in supplying information about the additives in their products, but for busy clinicians obtaining information this way can be time consuming.
At present patients presenting with symptoms, such as urticaria, that could be provoked by colourings or preservatives, or both, should avoid additives in drugs and food. When the additive content of a drug is unknown they should take a white tablet formulation as these are commonly free of colourings and preservatives and usually can be crushed and added to food for administration to children.
